Yifang Biotechnology (688382.SH) announced that the company plans to sign a transfer agreement with Lyvgen Biopharma Holdings Limited and its controlled companies.
Zhithong Finance APP news, Yifang Biotechnology (688382.SH) announced that the company plans to sign a "Transfer Agreement" with Lyvgen Biopharma Holdings Limited and its controlled companies (referred to as "Lyvgen", "the seller"). Lyvgen intends to transfer proprietary technology corresponding to no more than 3 target antibodies to the company, grant relevant licensed patent rights, and transfer other necessary materials, with a total transaction amount not exceeding RMB 1.5 million.
This related transaction is necessary for the development and operation of the company business, beneficial for the company to improve research and development efficiency, accelerate the progress of new drug development, and further expand the existing product pipeline.